U-M Tech Transfer is the gateway for publishing mobile apps for the University of Michigan and is responsible for publishing apps developed by or sponsored by U-M faculty, staff and graduate students. Tech Transfer can provide value and assistance throughout the publishing process, including the following:
- Determine if your application is university-owned
- Provide best practices and other points to consider when developing your app
- Determine potential need for IRB, FDA, or HIPAA regulatory compliance
- Assist with licensing considerations and process
- Provide guidance on requirements to submit your app to the Apple App Store and/or Google Play Store.
- Share analytics as desired while your app is live.
- Update apps as needed.
- Determine a maintenance plan for your app.
For more information on mobile publishing, please call 734.764.0614.
Is Tech Transfer responsible for publishing your app?
If the developers or sponsors of your app include U-M faculty, staff, or graduate students, then Tech Transfer is likely responsible for publishing the app. If Tech Transfer is publishing your app, please complete and submit an invention disclosure form online or manually here. We cannot start the publishing process without a complete invention disclosure form.
- Involve Tech Transfer early in the process. When you have an idea, talk to Tech Transfer to walk through requirements and potential considerations.
- Determine if IRB, FDA, or HIPAA compliance applies. Mobile applications deemed likely to meet the definition of an FDA-regulated medical device can only be published under IRB or similar oversight.
- Complete a U-M branding review if you play to use U-M branding in your app. Tech Transfer can provide you with contact information.
- Consider accessibility as you develop your app. Some resources can be found at
- End User Licensing Agreements (EULAs). Tech Transfer can assist in evaluating licensing considerations.
- While U-M typically uses the standard Apple and Google EULA, you may want to consider using a custom agreement
- Custom EULAs are typically required for medical apps, apps that involve HIPAA regulation or apps entailing FDA regulation
Royalty and Revenue Distributions
Both Apple and Google receive a 30% commission on the net sales for all applications. Royalty and revenue distributions are handled according to the standard Tech Transfer process on the remaining 70%.
Publishing Process Overview (iOS and Android)
U-M Information and Technology Services (ITS) and TechTransfer work together submit your source code and other required assets for publication to the App Store and Google Play Store.
Generally, three types of submissions can be made:
- New app. The primary elements required for publishing a new app are the app’s
- Source code
- Graphics assets (screenshots, icons, etc.)
- App update. The primary elements required for updating an existing app are the app’s
- Updated source code
- Release notes (what’s new)
- Graphics assets (screenshots, icons, etc.), if applicable
- Beta testing. Both iOS and Android apps can be submitted for beta testing prior to release to the stores. The primary elements required for testing is similar to that for new apps and app updates
- Source code
- Information for testers on what to test
- Graphics assets (screenshots, icons, etc.) – required for Android only
- List of testers’ email addresses
Tech Transfer will provide you with a detailed app submission form so that you can provide us with the source code and assets necessary to submit your app to the stores for review and approval. After the app is submitted for review and approval, Tech Transfer will apprise you of the status throughout the process.
Apple and Google do not provide specific time frames for their app review, and review times may vary by app. Apple reports that on average, 50% of apps are reviewed within 24 hours and over 90% are reviewed in 48 hours.
PLEASE NOTE: Distribution of applications in China via Google Play Store is not supported. Because of government restrictions on content and the market deployment approaches in China, applications that require this market are not supported. Our office continues to evaluate options for this but currently no acceptable substitutes which provides consistent market coverage and approaches are available.